CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43 enrolled
Drug / intervention
Study-provided Moderna mRNA-1273 COVID-19 vaccine +2 morebiological
Likely dose
Study-provided Moderna mRNA-1273 COVID-19 vaccine 100 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04952402
NCT04952402Phase 4Completed
CompareCT.gov

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 7, 2021·Updated May 24, 2023

In Brief

A Phase 4 clinical trial evaluating Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, and 1 other intervention for Covid19 and SARS-CoV2 Infection. Completed, enrolled 43 participants across 6 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, SARS-CoV2 Infection
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 7, 2021
Enrollment StartJul 9, 2021
Primary CompletionFeb 28, 2022
Study CompletionJan 10, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.0 years ago

Interventions

Study-provided Moderna mRNA-1273 COVID-19 vaccinebiological

Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).

Community-provided Moderna mRNA-1273 COVID-19 Vaccinebiological

Participants received a two-dose series.

Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccinebiological

Participants received a two-dose series.